How folate metabolism affects colorectal cancer development and treatment; a story of heterogeneity and pleiotropy.

[1]  M. Scheurer,et al.  Gene-Environment Interactions and the Risk of Childhood Acute Lymphoblastic Leukemia: Exploring the Role of Maternal Folate Genes and Folic Acid Fortification , 2014, Pediatric hematology and oncology.

[2]  Teri E. Klein,et al.  Clinical Pharmacogenetics Implementation Consortium Guidelines for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing , 2013, Clinical pharmacology and therapeutics.

[3]  Jane Skinner,et al.  Evaluating Predictive Pharmacogenetic Signatures of Adverse Events in Colorectal Cancer Patients Treated with Fluoropyrimidines , 2013, PloS one.

[4]  C. Lewis,et al.  Pharmacogenetic variants in the DPYD, TYMS, CDA and MTHFR genes are clinically significant predictors of fluoropyrimidine toxicity , 2013, British Journal of Cancer.

[5]  M. Crous-Bou,et al.  Pharmacogenomics in colorectal cancer: a genome-wide association study to predict toxicity after 5-fluorouracil or FOLFOX administration , 2012, The Pharmacogenomics Journal.

[6]  Mira Ayadi,et al.  Gene Expression Classification of Colon Cancer into Molecular Subtypes: Characterization, Validation, and Prognostic Value , 2013, PLoS medicine.

[7]  Lewis C Cantley,et al.  A colorectal cancer classification system that associates cellular phenotype and responses to therapy , 2013, Nature Medicine.

[8]  W. Ding,et al.  Methionine Synthase A2756G Polymorphism and Risk of Colorectal Adenoma and Cancer: Evidence Based on 27 Studies , 2013, PloS one.

[9]  D. Kerr,et al.  Use of multivariate analysis to suggest a new molecular classification of colorectal cancer , 2013, The Journal of pathology.

[10]  R. Uauy,et al.  Impact of folic acid fortification of flour on neural tube defects: a systematic review , 2012, Public Health Nutrition.

[11]  Q. Mei,et al.  The Polymorphisms in Methylenetetrahydrofolate Reductase, Methionine Synthase, Methionine Synthase Reductase, and the Risk of Colorectal Cancer , 2012, International journal of biological sciences.

[12]  J. Eshleman,et al.  Analysis of Polymorphisms and Haplotype Structure of the Human Thymidylate Synthase Genetic Region: A Tool for Pharmacogenetic Studies , 2012, PloS one.

[13]  Y. Loke,et al.  Functional polymorphisms of folate metabolism and response to chemotherapy for colorectal cancer, a systematic review and meta-analysis , 2012, Pharmacogenetics and genomics.

[14]  P. Zhu,et al.  Capecitabine plus oxaliplatin compared with 5-fluorouracil plus oxaliplatin in metastatic colorectal cancer: Meta-analysis of randomized controlled trials. , 2012, Oncology letters.

[15]  R. Altman,et al.  PharmGKB summary: carbamazepine pathway , 2011, Pharmacogenetics and genomics.

[16]  S. Kern,et al.  Reexamining a proposal , 2011, Cancer biology & therapy.

[17]  U. Vogel,et al.  The association of polymorphisms in 5-fluorouracil metabolism genes with outcome in adjuvant treatment of colorectal cancer. , 2011, Pharmacogenomics.

[18]  F. Cianchi,et al.  Thymidylate synthase expression and genotype have no major impact on the clinical outcome of colorectal cancer patients treated with 5-fluorouracil. , 2011, Pharmacological research.

[19]  Y. Wettergren,et al.  Gene polymorphisms MTHFRC677T and MTRA2756G as predictive factors in adjuvant chemotherapy for stage III colorectal cancer. , 2011, Anticancer research.

[20]  D. Chang,et al.  The CpG island methylator phenotype may confer a survival benefit in patients with stage II or III colorectal carcinomas receiving fluoropyrimidine-based adjuvant chemotherapy , 2011, BMC Cancer.

[21]  S. Ackland,et al.  Association of thymidylate synthase enhancer region polymorphisms with thymidylate synthase activity in vivo , 2011, The Pharmacogenomics Journal.

[22]  U. Vogel,et al.  Combinations of Polymorphisms in Genes Involved in the 5-Fluorouracil Metabolism Pathway Are Associated with Gastrointestinal Toxicity in Chemotherapy-Treated Colorectal Cancer Patients , 2011, Clinical Cancer Research.

[23]  J. Cubiella,et al.  5-Fluorouracil adjuvant chemotherapy does not increase survival in patients with CpG island methylator phenotype colorectal cancer. , 2011, Gastroenterology.

[24]  S. De,et al.  DNA secondary structures and epigenetic determinants of cancer genome evolution , 2010, Nature Structural &Molecular Biology.

[25]  Russ B Altman,et al.  PharmGKB summary: fluoropyrimidine pathways. , 2010, Pharmacogenetics and genomics.

[26]  S. Duthie.  Folate and cancer: how DNA damage, repair and methylation impact on colon carcinogenesis , 2011, Journal of Inherited Metabolic Disease.

[27]  Elizabeth L. Barry,et al.  Association between Folate Levels and CpG Island Hypermethylation in Normal Colorectal Mucosa , 2010, Cancer Prevention Research.

[28]  K. Yu,et al.  Methionine synthase A2756G polymorphism and cancer risk: a meta-analysis , 2010, European Journal of Human Genetics.

[29]  P. Stover,et al.  One-carbon metabolism-genome interactions in folate-associated pathologies. , 2009, The Journal of nutrition.

[30]  M. Parmar,et al.  Association of molecular markers with toxicity outcomes in a randomized trial of chemotherapy for advanced colorectal cancer: the FOCUS trial. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  S. Vollset,et al.  Cancer incidence and mortality after treatment with folic acid and vitamin B12. , 2009, JAMA.

[32]  L. Marchand,et al.  Meta- and pooled analyses of the methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism and colorectal cancer: a HuGE-GSEC review. , 2009, American journal of epidemiology.

[33]  J. Lau,et al.  MTHFR gene polymorphisms and response to chemotherapy in colorectal cancer: a meta-analysis. , 2009, Pharmacogenomics.

[34]  A. Frigo,et al.  Predictors of survival and toxicity in patients on adjuvant therapy with 5-fluorouracil for colorectal cancer , 2009, British Journal of Cancer.

[35]  H. Sánchez,et al.  Colon cancer in Chile before and after the start of the flour fortification program with folic acid , 2009, European Journal of Gastroenterology and Hepathology.

[36]  Ling Xia,et al.  Chemoresistant colorectal cancer cells, the cancer stem cell phenotype, and increased sensitivity to insulin-like growth factor-I receptor inhibition. , 2009, Cancer research.

[37]  C. Stehouwer,et al.  Red blood cell folate vitamer distribution in healthy subjects is determined by the methylenetetrahydrofolate reductase C677T polymorphism and by the total folate status. , 2007, The Journal of nutritional biochemistry.

[38]  H. Powers.  Folic acid under scrutiny. , 2007, The British journal of nutrition.

[39]  I. Rosenberg,et al.  A Temporal Association between Folic Acid Fortification and an Increase in Colorectal Cancer Rates May Be Illuminating Important Biological Principles: A Hypothesis , 2007, Cancer Epidemiology Biomarkers & Prevention.

[40]  Elizabeth L. Barry,et al.  Folic acid for the prevention of colorectal adenomas: a randomized clinical trial. , 2007, JAMA.

[41]  D. Wald,et al.  Folic acid, homocysteine, and cardiovascular disease: judging causality in the face of inconclusive trial evidence , 2006, BMJ : British Medical Journal.

[42]  M. Gorospe,et al.  Differential Stability of Thymidylate Synthase 3′-Untranslated Region Polymorphic Variants Regulated by AUF1* , 2006, Journal of Biological Chemistry.

[43]  P. Finglas,et al.  Research goals for folate and related B vitamin in Europe , 2006, European Journal of Clinical Nutrition.

[44]  Yoshiro Saito,et al.  Polymorphic tandem repeat sequences of the thymidylate synthase gene correlates with cellular-based sensitivity to fluoropyrimidine antitumor agents , 2005, Cancer Chemotherapy and Pharmacology.

[45]  A. Roddam,et al.  Folate intake and colorectal cancer risk: A meta‐analytical approach , 2005, International journal of cancer.

[46]  D. Tregouet,et al.  Thymidylate Synthase Gene Polymorphism Predicts Toxicity in Colorectal Cancer Patients Receiving 5-Fluorouracil-based Chemotherapy , 2004, Clinical Cancer Research.

[47]  S. Groshen,et al.  A 6 bp polymorphism in the thymidylate synthase gene causes message instability and is associated with decreased intratumoral TS mRNA levels. , 2004, Pharmacogenetics.

[48]  J. Little,et al.  Polymorphisms in genes involved in folate metabolism and colorectal neoplasia: a HuGE review. , 2004, American journal of epidemiology.

[49]  A. Matakidou,et al.  Thymidylate synthase expression and prognosis in colorectal cancer: a systematic review and meta-analysis. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  G. Watanabe,et al.  Identification and functional analysis of single nucleotide polymorphism in the tandem repeat sequence of thymidylate synthase gene. , 2003, Cancer research.

[51]  H. Lenz,et al.  A novel single nucleotide polymorphism within the 5' tandem repeat polymorphism of the thymidylate synthase gene abolishes USF-1 binding and alters transcriptional activity. , 2003, Cancer research.

[52]  P. Johnston,et al.  5-Fluorouracil: mechanisms of action and clinical strategies , 2003, Nature Reviews Cancer.

[53]  R. Rozen,et al.  Methylenetetrahydrofolate reductase polymorphism in advanced colorectal cancer: a novel genomic predictor of clinical response to fluoropyrimidine-based chemotherapy. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[54]  R. Schilsky,et al.  First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[55]  E. Van Cutsem,et al.  Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[56]  H. McLeod,et al.  Polymorphism in the thymidylate synthase promoter enhancer region in colorectal cancer. , 2001, International journal of oncology.

[57]  C. Weitzel,et al.  Capecitabine (Xeloda) improves medical resource use compared with 5-fluorouracil plus leucovorin in a phase III trial conducted in patients with advanced colorectal carcinoma. , 2001, European journal of cancer.

[58]  P. Vreken,et al.  Heterozygosity for a point mutation in an invariant splice donor site of dihydropyrimidine dehydrogenase and severe 5-fluorouracil related toxicity. , 1997, European journal of cancer.

[59]  A. Zaniboni,et al.  Adjuvant chemotherapy in colorectal cancer with high-dose leucovorin and fluorouracil: impact on disease-free survival and overall survival. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[60]  S. Daly,et al.  Thermolabile variant of 5, 10-methylenetetrahydrofolate reductaseassociated with low red-cell folates: implications for folate intake recommendations , 1997, The Lancet.

[61]  D. Weir,et al.  Folate levels and neural tube defects. Implications for prevention. , 1995, JAMA.

[62]  N. Horie,et al.  Functional analysis and DNA polymorphism of the tandemly repeated sequences in the 5'-terminal regulatory region of the human gene for thymidylate synthase. , 1995, Cell structure and function.

[63]  R. Matthews,et al.  A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase , 1995, Nature Genetics.

[64]  Sajeev P. Cherian,et al.  Human chromosome 3 corrects mismatch repair deficiency and microsatellite instability and reduces N-methyl-N'-nitro-N-nitrosoguanidine tolerance in colon tumor cells with homozygous hMLH1 mutation. , 1994, Cancer research.

[65]  W. Scheithauer,et al.  Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. , 1993, BMJ.

[66]  K. Laurence,et al.  Double-blind randomised controlled trial of folate treatment before conception to prevent recurrence of neural-tube defects. , 1981, British medical journal.

[67]  W. Wilmanns,et al.  Cobalamin Dependent Methionine Synthesis and Methyl‐Folate‐Trap in Human Vitamin B12 Deficiency , 1977, British journal of haematology.

[68]  J. McCulloch,et al.  CHAPTER 7 – Implications for Prevention , 1972 .

[69]  V. Herbert,et al.  Interrelations of vitamin B12 and folic acid metabolism: folic acid clearance studies. , 1962, The Journal of clinical investigation.

[70]  E. Stokstad,et al.  SYNTHESIS OF A COMPOUND IDENTICAL WITH THE L. CASEI FACTOR ISOLATED FROM LIVER. , 1945, Science.

[71]  P. W. Clutterbuck,et al.  A new factor in the production and cure of macrocytic anaemias and its relation to other haemopoietic principles curative in pernicious anaemia. , 1937, Biochemical Journal.